ArticleNPJ precision oncology2025
A promptable CT foundation model for solid tumor evaluation.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Promptable 3D-CT Foundation Model-Based Approach for Pulmonary Embolism.Cardiovascular and interventional radiology · 2026Article
- Review
- Radiotherapy for primary bone tumors: current techniques and integration of artificial intelligence-a review.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinogenesis is inherently complex, resulting in heterogeneous tumors with variable outcomes and frequent metastatic potential. Conventional longitudinal evaluation methods like RECIST 1.1 remain labor-intensive and prone to measurement errors, while existing AI solutions face critical limitations due to tumor heterogeneity, insufficient annotations, and lack of user interaction. We developed ONCOPILOT, an interactive CT-based foundation model dedicated to 3D tumor segmentation, significantly refining RECIST 1.1 evaluations with active radiologist engagement. Trained on more than 8000 CT scans, ONCOPILOT employs intuitive visual prompts, including point-click, bounding boxes, and edit-points. It attains segmentation accuracy that matches or exceeds state-of-the-art methods, provides radiologist-level precision for RECIST 1.1 measurements, reduces inter-observer variability, and enhances workflow efficiency. Integrating clinical expertise with interactive AI capabilities, ONCOPILOT facilitates widespread access to advanced biomarkers, notably volumetric tumor analyses, thereby supporting improved clinical decision-making, patient stratification, and accelerating advancements in oncology research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.